Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer Patients
A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma.
Cost Effectiveness of CAR T-Cell Therapy Depends on Long-Term Outcomes
Researchers conducted a cost-effectiveness analysis on the two FDA-approved CAR T-cell therapies for diffuse large B-cell lymphoma.
Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid Tumors
Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.
For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy Excites
A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.